Cargando…

Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C

Patients with chronic hepatitis C virus (HCV) develop hepatocellular carcinoma (HCC) regardless of achieving a sustained viral response (SVR). Because advanced liver fibrosis is a powerful risk factor for HCC, we analyzed the association between autotaxin (ATX), a liver fibrosis marker, and post-SVR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takemura, Kazuya, Takizawa, Etsuko, Tamori, Akihiro, Nakamae, Mika, Kubota, Hiroshi, Uchida-Kobayashi, Sawako, Enomoto, Masaru, Kawada, Norifumi, Hino, Masayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350226/ https://www.ncbi.nlm.nih.gov/pubmed/32630450 http://dx.doi.org/10.3390/ijms21124517

Ejemplares similares

Recent Advances in Antiviral Therapy for Chronic Hepatitis C
por: Tamori, Akihiro, et al.
Publicado: (2016)

Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed
por: Nonomura, Ayami, et al.
Publicado: (2021)

Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response
por: Itami-Matsumoto, Saori, et al.
Publicado: (2019)

Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed
por: Yoshida, Kanako, et al.
Publicado: (2017)

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy
por: Yoshida, Kanako, et al.
Publicado: (2021)

The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
por: Fujii, Hideki, et al.
Publicado: (2021)

Hepatitis B virus infection and alcohol consumption
por: Iida-Ueno, Ayako, et al.
Publicado: (2017)

Validation of a two‐step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis
por: Fujii, Hideki, et al.
Publicado: (2021)

Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication
por: Motoyama, Hiroyuki, et al.
Publicado: (2018)

Correction: Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication
por: Motoyama, Hiroyuki, et al.
Publicado: (2018)

Effect of Caffeine-Containing Beverage Consumption on Serum Alanine Aminotransferase Levels in Patients with Chronic Hepatitis C Virus Infection: A Hospital-Based Cohort Study
por: Sasaki, Yachiyo, et al.
Publicado: (2013)

Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma
por: Hai, Hoang, et al.
Publicado: (2017)

High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use
por: Tamori, Akihiro, et al.
Publicado: (2020)

Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein
por: Yamamoto, Akira, et al.
Publicado: (2021)

Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization
por: Odagiri, Naoshi, et al.
Publicado: (2020)

A case of primary small cell carcinoma of the liver that was treated with chemotherapy
por: Morikawa, Hiroyasu, et al.
Publicado: (2008)

A Case of IgG1-Lambda Multiple Myeloma With Hyperviscosity Syndrome and Cryoglobulinemia: Identification of the Subclass Fraction by Immunoelectrophoresis and Immunofixation Electrophoresis
por: Tazoe, Kumiyo, et al.
Publicado: (2023)

Successful Transcatheter Arterial Embolization for Hemothorax from a Spontaneous Rupture of Hepatocellular Carcinoma Metastasis to the Chest Wall in an Elderly Patient
por: Suoh, Maito, et al.
Publicado: (2021)

Risk factors for hepatocellular carcinoma in treated chronic hepatitis C patients–Relationship to smoking and alcohol
por: Matsuura, Tomoka, et al.
Publicado: (2020)

Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma
por: Uchida‐Kobayashi, Sawako, et al.
Publicado: (2022)

The Administration of Tenofovir Disoproxil Fumarate for Pregnant Japanese Women with Chronic Hepatitis B
por: Suoh, Maito, et al.
Publicado: (2020)

Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment
por: Kozuka, Ritsuzo, et al.
Publicado: (2022)

Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma
por: Suoh, Maito, et al.
Publicado: (2020)

Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma
por: Dong, Minh Phuong, et al.
Publicado: (2020)

Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis
por: Kotani, Kohei, et al.
Publicado: (2023)

M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals
por: Saleh, Shereen A, et al.
Publicado: (2020)

Comparison of Hepatocellular Carcinoma miRNA Expression Profiling as Evaluated by Next Generation Sequencing and Microarray
por: Murakami, Yoshiki, et al.
Publicado: (2014)

Suppression of intrahepatic cholangiocarcinoma cell growth by SKI via upregulation of the CDK inhibitor p21
por: Kawamura, Etsushi, et al.
Publicado: (2022)

Significant Correlation Between Grip Strength and m2bpgi in Patients with Chronic Liver Diseases
por: Nishikawa, Hiroki, et al.
Publicado: (2019)

Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C
por: Yamazaki, Tomoo, et al.
Publicado: (2018)

Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance?
por: Enomoto, Masaru, et al.
Publicado: (2022)

Development of a novel anti-hepatitis B virus agent via Sp1
por: Hayakawa, Michiyo, et al.
Publicado: (2020)

Author Correction: Development of a novel anti-hepatitis B virus agent via Sp1
por: Hayakawa, Michiyo, et al.
Publicado: (2020)

Severity of Liver Fibrosis Is Associated with the Japanese Diet Pattern and Skeletal Muscle Mass in Patients with Nonalcoholic Fatty Liver Disease
por: Matsumoto, Yoshinari, et al.
Publicado: (2023)

Another name for autotaxin
por: Dove, Alan W.
Publicado: (2002)

Roles of Autotaxin/Autotaxin-Lysophosphatidic Acid Axis in the Initiation and Progression of Liver Cancer
por: She, Sha, et al.
Publicado: (2022)

Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C
por: Takakusagi, Satoshi, et al.
Publicado: (2021)

Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B
por: Bui, Hoang Huu, et al.
Publicado: (2023)

Urine autotaxin levels reflect the disease activity of sarcoidosis
por: Murakami, Koji, et al.
Publicado: (2022)

Chemical Evolution of Autotaxin Inhibitors
por: Albers, Harald M. H. G., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9900am62o573blpnmpec22h8q0